Drug Trial News

RSS

Sanford Health clinical trial testing effectiveness of investigational cancer drug nivolumab

People with Merkel cell, gynecological, gastric and head and neck cancers may be eligible to participate in a clinical trial at Sanford Health testing the effectiveness of an investigational drug called nivolumab.

18 Feb 2016

New drug combination shows promise for patients with non-small cell lung cancer

Lung cancer is the most common cause of cancer-related death in the United States resulting in more than 158,000 deaths each year. With a 5-year survival rate at only 18 percent, the development of new and improved treatment options is needed.

18 Feb 2016

WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

The Walter Reed Army Institute of Research began vaccinations today in a Phase 1 clinical trial to evaluate the safety and immune response of a vaccine candidate to prevent Middle East Respiratory Syndrome (MERS).

17 Feb 2016

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Celator Pharmaceuticals, Inc. today announced that the Phase 3 clinical trial of VYXEOS (cytarabine:daunorubicin) Liposome for Injection (also known as CPX-351) in patients with untreated high-risk (secondary) acute myeloid leukemia (AML) has reached its pre-specified number of events required for the analysis of overall survival.

16 Feb 2016

Experimental vaccine shows effectiveness in Ebola vaccine trial

An experimental vaccine combined with an innovative way of vaccinating people has resulted in an estimated 100 percent efficacy of the vaccine against the Ebola virus in West Africa -- and the approach could establish a new way of responding to outbreaks of emerging pathogens, including the Zika virus.

16 Feb 2016

First patients dosed in Neurotrope's Bryostatin-1 Phase 2b trial for treatment of advanced Alzheimer’s disease

Neurotrope, Inc. today announced that the first patients have been dosed in the Company’s Phase 2b clinical trial of its lead candidate, Bryostatin-1, for the treatment of advanced Alzheimer’s disease.

16 Feb 2016

Most stage III melanoma patients do not benefit from interferon treatment

Final results for the Sunbelt Melanoma Trial, published online this month in the Journal of Clinical Oncology, show that thanks to current diagnostic techniques, most stage III melanoma patients do not benefit from treatment with interferon.

15 Feb 2016

New UAB research shows association between verapamil use and lower glucose levels in diabetics

A new University of Alabama at Birmingham research paper published in the journal Diabetes Research and Clinical Practice shows for the first time that there is an association of verapamil use and lower fasting glucose levels in humans with diabetes.

15 Feb 2016

Modulation of opioid system may improve effectiveness of drugs for treatment-resistant depression

A clinical trial of an experimental drug for treatment-resistant major depression finds that modulation of the endogenous opioid system may improve the effectiveness of drugs that target the action of serotonin and related monoamine neurotransmitters.

12 Feb 2016

Oral therapeutic drug shows promise against recurrent C. difficile infection

Results from a Phase 1b/2 trial suggest that an investigational microbiome-based, oral therapeutic drug is effective for the treatment of recurrent C. difficile infection. In a paper published online in the Journal of Infectious Diseases, a multi-institutional research team reports that treatment with the preparation, containing the spores of approximately 50 species of beneficial bacteria, successfully prevented recurrence of C. difficile infection (CDI) in patients with a history of multiple recurrent disease.

10 Feb 2016

IDMC recommends continuation of PM1183 Phase III trial in platinum-resistant ovarian cancer patients

PharmaMar announced today that the Independent Data Monitoring Committee has notified the Company of its recommendation that the Phase III (CORAIL) trial currently under way with PM1183 in platinum-resistant ovarian cancer patients should continue without any changes.

8 Feb 2016

OASIS clinical study evaluates investigational medication for treatment of UC

Ulcerative Colitis (UC) is a chronic disease of the colon that causes the colon to become inflamed and forms ulcers. UC is a type of irritable bowel disease (IBD), which is a term that describes conditions with chronic or recurring inflammation of the gastrointestinal tract.

3 Feb 2016

Use of antenatal steroids during late preterm delivery prevents neonatal respiratory complications

In a study to be presented on Feb. 4 in the oral plenary session at 8 a.m. EST, at the Society for Maternal-Fetal Medicine's annual meeting, The Pregnancy Meeting, in Atlanta, researchers with the Eunice Kennedy Shriver National Institute of Child Health and Human Development and Maternal-Fetal Medicine Units Network found that the administration of antenatal steroids in pregnancies at risk for late preterm delivery prevents respiratory and other neonatal complications.

2 Feb 2016

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair and regeneration, today announced that its U.S. joint venture with G-treeBNT, ReGenTree LLC, has completed enrollment of its Phase 2b/3 dry eye trial in the U.S.

29 Jan 2016

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

The first clinical trial to move forward as part of the Van Andel Research Institute-Stand Up To Cancer (VARI-SU2C) Epigenetics Dream Team will target metastatic colorectal cancer, the second leading cause of cancer deaths among men and women combined in the U.S.

29 Jan 2016

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

AbbVie, in cooperation with Neurocrine Biosciences, Inc., today announced the initiation of the first of two planned Phase 3 clinical studies evaluating the safety and efficacy of Elagolix alone or in combination with add-back therapy compared to placebo.

29 Jan 2016

Dysport phase III study results in children with cerebral palsy with lower limb spasticity published in Pediatrics

Ipsen today announced that the scientific journal Pediatrics published the detailed results of the phase III randomized study showing both the efficacy and the safety of Dysport in the treatment of dynamic equinus foot deformity, a condition associated with cerebral palsy in children.

28 Jan 2016

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

Building upon more than two decades of basic research conducted at Children's Hospital Los Angeles, Araz Marachelian, MD, of CHLA, and her colleagues at pediatric academic centers across the U. S., have shown that an immunotherapy that until now has only been available to patients enrolled in research studies, is equivalent to the product that has been manufactured for commercial use and can be made available to all patients.

28 Jan 2016

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Bristol-Myers Squibb Company today announced that the U.S. Food and Drug Administration has approved Opdivo in combination with Yervoy for the treatment of patients with BRAF V600 wild-type and BRAF V600 mutation-positive unresectable or metastatic melanoma.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

Drug Trial News

Sanford Health clinical trial testing effectiveness of investigational cancer drug nivolumab

New drug combination shows promise for patients with non-small cell lung cancer

WRAIR begins Phase 1 clinical trial to evaluate MERS vaccine candidate

Celator provides update on Phase 3 clinical trial of VYXEOS in patients with untreated high-risk AML

Experimental vaccine shows effectiveness in Ebola vaccine trial

First patients dosed in Neurotrope's Bryostatin-1 Phase 2b trial for treatment of advanced Alzheimer’s disease

Most stage III melanoma patients do not benefit from interferon treatment

New UAB research shows association between verapamil use and lower glucose levels in diabetics

Modulation of opioid system may improve effectiveness of drugs for treatment-resistant depression

Oral therapeutic drug shows promise against recurrent C. difficile infection

IDMC recommends continuation of PM1183 Phase III trial in platinum-resistant ovarian cancer patients

OASIS clinical study evaluates investigational medication for treatment of UC

Use of antenatal steroids during late preterm delivery prevents neonatal respiratory complications

RegeneRx Biopharmaceuticals announces completion of enrollment for Phase 2b/3 dry eye trial in U.S.

VARI-SU2C Epigenetics Dream Team supports new clinical trial that targets metastatic colorectal cancer

AbbVie announces initiation of first Elagolix Phase 3 study in patients with uterine fibroid

Dysport phase III study results in children with cerebral palsy with lower limb spasticity published in Pediatrics

Study leads to FDA approval of first immunotherapy for treatment of neuroblastoma

FDA expands use of Opdivo + Yervoy Regimen for BRAF V600 mutant and wild-type advanced melanoma

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News